Compare Enbridge Inc (ENB) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Enbridge Inc trades at $47.37 (market cap $105.81B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Enbridge Inc is far larger — about 10.3× Globus Medical Inc. Class A Common Stock's market cap, and Enbridge Inc pays a 5.91% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 92 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| ENB | GMED | |
|---|---|---|
Market Cap | $105.81B | $10.25B |
Volume | 3,872,535 | 1,059,528 |
Sector | Energy | Health |
52-Week High | $58.04 | $96.82 |
52-Week Low | $45.23 | $58.33 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $188.05B | $9.76B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $47.46, up 1.09% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly earnings beats. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%. Analyst consensus is split between Buy and Hold, with a $61.63 price target suggesting significant upside. The stock offers a 6% dividend yield, supported by stable cash flows from its midstream energy operations.
Outlook is mixed: robust EBITDA growth and strategic expansion into renewables provide long-term value, but rising debt levels and interest rate sensitivity pose risks. Near-term performance may hinge on Q3 2026 earnings versus the $0.38 estimate. Institutional interest remains strong, as seen in Nykredit's $51.75M purchase in September 2026.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
